Oren Beske, Ph.D.
Amalgamator of Business and Biology , ATUM
Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc., a start-up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.
Talk to Dr. Beske about these topics and more:
- Cell line development
- Leap-In Transposase and Transposons
Ready to Connect?
Would you like to invite a health science expert to participate in your next piece, program, panel, or partnership? Our team is standing by to help connect you to the right source and topic:
About ATUM
ATUM is a fully integrated California based CRDO (Contract Research & Development Organization) biotechnology industry leader. ATUM, over the last two decades, has served life science researchers by delivering the highest quality services including gene design and gene synthesis, protein engineering, protein production, Leap-In Transposase®, cell line development, and master cell banking (MCB). With a state-of-the-art machine learning platform, proprietary algorithms and our fully integrated Laboratory Information Management System (LIMS), ATUM takes you from virtual sequence to MCB with a click of a button. ATUM provides a continual commitment to innovation where services are built on bioengineered solutions to bring speed to market, supporting you from pre-clinical research through IND and beyond. For more information, visit atum.bio.
Save this page as a PDF
